On February 14, 2022, Kawin and YiChang HEC ChangJiang Pharmaceutical Co.,Ltd. (hereinafter referred to as HEC Pharm 东阳光药, stock code: 1558.HK) signed a strategic collaboration agreement on "HCV Elimination Plan". To achieve the goal of HCV elimination 2030, the two parties have agreed on a strategic collaboration based on their own hepatitis C cure drugs.

Kawin's high cure rate pan-genotype all-oral series of drugs for hepatitis C and Yimitasvir Phosphate Capsules of HEC Pharm obtained NDA in 2020. Yimitasvir was included into NRDL in 2021, and Coblopasvir was included into NRDL in 2020. Following the collaboration, Kawin will be responsible for the distribution of Yimitasvir by some areas of the country, which aims to cover the local medication needs of the major genotype of HCV patients. 

The two parties will explore further cooperation models based on dual advantages in R&D, marketing and sales, to help eliminate HCV in China.

NO Director Guo Hong of Z-Park’s Management Committee visits Kawin Technology